Marc Barry, M.D.

photo of marc barry

Associate Professor

Email: MarcBarry@salud.unm.edu


Interests:

  • Urologic Pathology
  • Medical Renal Pathology

Education and Certification Information

Fellowship:
Brigham and Women's Hospital (Jun 2007)
Urologic Pathology

Fellowship:
Brigham and Womens Hospital/Massachusetts Institute of Technology (Jul 2004)
Research Fellow

Fellowship:
Brigham and Womens Hospital (Jun 2003)
Medical Renal Pathology

Residency:
Brigham and Womens Hospital (Jul 2000)
Anatomic Pathology

Residency:
University College Dublin (Jun 1997)
Histopathology

Internship:
Mater Misericordiae Hospital (Jun 1996)
Medicine and Surgery

Medical School:
University College Dublin (UCD: M.D. 1995; M.Med.Sci. 1996)

Board Certifications:
Am Bd Pathology (Sub: Anatomic) : (Jul 2005)

Specialties:
Pathology, Anatomical
Surgical Pathology, Urologic Pathology, Nephropathology


Selected Publications:

  1. Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK: Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012; Jan 26 (epub ahead of print).

  2. Barry M, Dhillon P, Stampfer MJ, Perner S, Ma J, Giovannucci E, Kurth T, Mucci LA, Rubin MA: -Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians’ Health Study and Health Professionals Follow-up Study. Prostate. 2012 72(3):301-6.

  3. Singh P, Barry M, Tzamaloukas A: Goodpasture’s disease complicating human immunodeficiency virus infection. Clinical Nephrology 2011; 76(1): 74-7.

  4. Xu L, Begum S, Barry M, Crowley D, Yang L, Bronson RT, Hynes RO: GPR56 plays varying roles in endogenous cancer progression. Clin Exp Metastasis 2010(4); 27:241-9.

  5. Kempiah P, Danielson LA, Barry M, Kisiel W: Comparative effects of Aprotinin and human recombinant R24K KD1 on temporal renal function in Long-Evans rats. J. Pharmacology and Experimental Therapeutics. 2009; 331:1-6.

  6. Dhillon PK, Barry M, Stampfer MJ, Perner S, Fiorentino M, Fornari A, Ma J, Fleet J, Kurth T, Rubin MA, Mucci LA: Aberrant Cytoplasmic Expression of p63 and Prostate Cancer Mortality. Cancer Epidemiol Biomarkers Prev. 2009 Feb; 18(2): 595-600.

  7. Majumder P, Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, Sawyers CL, Signoretti S, Hahn WC, Loda M, Sellers WR: A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell, 2008, Aug 12; 14(2): 146-55.

  8. McCarty J, Barry M, Lacy-Hulbert A, Bronson RT, Crowley D, Savill J, Hynes RO: Genetic ablation of alphaV integrins in the developing eyelid leads to Squamous Carcinoma: A potential function for alphaV integrin as a tumor suppressor. American J Pathol 2008, Jun, 172(6):1740-7.

  9. Barry M, Perner SV, Johnson L, Rubin MA: Heterogeneity for TMPRSS-ERG gene fusion in mulifocal prostate cancer. Urology 2007, 70(4): 630-3.

  10. Lacy-Hulbert A, Smith AM, Tissire H, Barry M, Crowley D, Bronson RT, Roes JT, Savill JS, Hynes RO: Ulcerative Colitis and autoimmunity induced by loss of myeloid alphav integrins. Proc. Natl. Acad. Sci. USA 2007, Oct 2; 104(40): 15823-8.

Search PubMed:

Marc Barry on PubMed